Edward Carr, who serves as Chief Accounting Officer at Dianthus Therapeutics, Inc. (NASDAQ:DNTH), disposed of 43,682 shares of the firm's common stock on March 12, 2026, receiving aggregate proceeds of approximately $3.56 million. The sale prices reported for the transactions ranged from $80.71 to $85.53 per share.
Concurrently on March 12, Carr exercised options to purchase a total of 43,682 shares of Dianthus common stock. The option exercise prices were between $17.88 and $22.07 per share, resulting in a total exercise cost of $893,259.
These insider transactions occurred while DNTH shares have experienced a substantial gain over the trailing year, rising 265% according to InvestingPro data cited on the company. At the time of reporting the stock was trading at $77.86. An InvestingPro note characterizes the shares as being in overbought territory, and its Fair Value analysis indicates the stock is slightly overvalued at current levels.
Separately, Dianthus completed a large public offering that generated roughly $719 million in gross proceeds. That transaction comprised the sale of 8,470,989 shares of common stock at $81.00 per share, a total that included shares sold under the underwriters’ option to purchase additional shares. The company also issued pre-funded warrants exercisable for up to 402,468 shares at $80.999 per warrant.
Earlier disclosures had indicated the pricing of a $625 million common stock offering at the same $81.00 per-share level. In addition to those completed offerings, the company announced a new $400 million stock offering intended to support ongoing clinical and preclinical development activities.
On the clinical front, Raymond James upgraded Dianthus to a Strong Buy following what it described as positive interim results from the Phase 3 CAPTIVATE study in patients with chronic inflammatory demyelinating polyneuropathy. Raymond James also increased its price target to $123. Clear Street similarly raised its price target to $130 and maintained a Buy rating, citing encouraging trial data.
Summary
On March 12, 2026, Dianthus Therapeutics’ CAO sold 43,682 shares for about $3.56 million and exercised options to acquire the same number of shares at exercise prices totaling $893,259. These moves coincide with substantial equity raises, analyst upgrades tied to interim trial data, and a significant run-up in the stock over the last year.
Key points
- Insider transaction: CAO Edward Carr sold 43,682 shares at $80.71 to $85.53 per share, totaling roughly $3.56 million.
- Option exercise: Carr exercised options to purchase 43,682 shares at $17.88 to $22.07 per share, with aggregate exercise costs of $893,259.
- Capital markets activity and clinical updates: Dianthus completed a $719 million offering, previously priced a $625 million offering, and announced a new $400 million offering, alongside positive interim Phase 3 data and analyst price-target increases.
Risks and uncertainties
- Valuation caution: InvestingPro flags DNTH as being in overbought territory and its Fair Value analysis suggests shares are slightly overvalued at current prices, introducing valuation risk for investors.
- Equity dilution: Large and consecutive stock offerings, including the $719 million raise and a new $400 million offering, represent potential dilution risk for existing shareholders.
- Clinical program dependence: The company's valuation and analyst enthusiasm cite interim Phase 3 results; future developments in clinical and preclinical programs will influence investor sentiment and share performance.
Information in this article is limited to the transactions, financing events, market observations, and analyst actions reported. Where details were not provided in source disclosures, this article does not infer additional motives or outcomes.